Identification and Synthesis of a Novel Selective Partial PPARδ Agonist with Full Efficacy on Lipid Metabolism In Vitro and In Vivo
摘要:
The aim was to identify a novel selective PPAR delta agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo. Using the triple PPAR alpha,gamma,delta agonist 1 as the structural starting point, we wanted to investigate the possibility of obtaining selective PPAR delta agonists by modifying only the acidic part of 1, while holding the lipophilic half of the molecule constant. The structure-activity relationship was guided by in vitro transactivation data using the human PPAR receptors, FFA oxidation efficacy performed in the rat muscle L6 cell line, and in vivo rat pharmacokinetic properties. Compound 7 ([4-[3,3-bis-(4-bromo-phenyl)-allylthio]-2-chloro-phenoxy]-acetic acid) was identified as a selective, partial agonist with good oral pharmacokinetic properties in rat. Chronic treatment of high fat fed ApoB100/CETP-Tgn mice with 7 corrected the plasma lipid parameters and improved insulin sensitivity. These data suggest that selective PPAR delta agonists have the potential to become a novel treatment of dyslipidemia.
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR&dgr; suptype.
Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
申请人:Jeppesen Lone
公开号:US06869967B2
公开(公告)日:2005-03-22
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.
NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC.
申请人:NOVO NORDISK A/S
公开号:EP1414778A1
公开(公告)日:2004-05-06
US6869967B2
申请人:——
公开号:US6869967B2
公开(公告)日:2005-03-22
[EN] NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC.<br/>[FR] NOUVEAUX DERIVES D'ACIDE CARBOXYLIQUE ET LEUR UTILISATION COMME ANTIDIABETIQUES, ETC.
申请人:NOVO NORDISK AS
公开号:WO2003011807A1
公开(公告)日:2003-02-13
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.